Novo Nordisk Aktie

39,25 EUR +0,07 EUR +0,18 %

12:45:18

STU

39,24 EUR -0,12 EUR -0,29 %

12:28:57

GVIE

Novo Nordisk jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.169,59 Mrd. EUR

KGV14,11Div. Rendite3,60%

WKNA3EU6F

ISINDK0062498333

SymbolNONOF

Novo Nordisk Aktien News

Sortieren:Datum Meistgelesen

15.07.25ZacksNovo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?

14.07.25ZacksInvestors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

10.07.25ZacksNovo Nordisk (NVO) Beats Stock Market Upswing: What Investors Need to Know

10.07.25ZacksThe Zacks Analyst Blog Highlights SAP SE, Novo Nordisk, Thermo Fisher Scientific and FONAR

10.07.25MotleyFool3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly

09.07.25ZacksTop Research Reports for SAP, Novo Nordisk & Thermo Fisher

09.07.25ZacksIs Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?

08.07.25BenzingaDoes Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval

07.07.25BenzingaHims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits

07.07.25ZacksWhy Novo Nordisk (NVO) is a Top Value Stock for the Long-Term

02.07.25MotleyFoolThis GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk

01.07.25ZacksNovo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note

01.07.25BenzingaNovo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report

30.06.25ZacksNovo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

12.06.25GlobeNewswireNovo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

10.06.25GlobeNewswireADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care

16.05.25GlobeNewswireNovo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

14.05.25GlobeNewswireNovo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

12.05.25GlobeNewswireNovo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presente

09.05.25GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

07.05.25GlobeNewswireNovo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025

03.04.25GlobeNewswireNovo Nordisk announces changes in Executive Management

29.03.25GlobeNewswireNovo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

29.03.25GlobeNewswireOzempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

27.03.25GlobeNewswireResolutions from the Annual General Meeting of Novo Nordisk A/S

24.03.25GlobeNewswireThe United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

10.03.25GlobeNewswireNovo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial

27.02.25GlobeNewswireNovo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

07.02.25GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

07.02.25GlobeNewswireNovo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

05.02.25GlobeNewswireNovo Nordisk files annual report with the SEC

05.02.25GlobeNewswireNovo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

04.02.25GlobeNewswireNovo Nordisk A/S - share repurchase programme

27.01.25GlobeNewswireNovo Nordisk A/S - share repurchase programme

24.01.25GlobeNewswireNovo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

20.01.25GlobeNewswireNovo Nordisk A/S - share repurchase programme

17.01.25GlobeNewswireNovo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

13.01.25GlobeNewswireNovo Nordisk A/S - share repurchase programme

08.01.25GlobeNewswireValo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases

Novo Nordisk News

Novo Nordisk News: auf dieser Seite finden Sie alle Novo Nordisk News und Nachrichten zur Novo Nordisk Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novo Nordisk News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novo Nordisk News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.